33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic highrisk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Evolve CLL/SLL study (SWOG S1925; NCT#04269902)
    Meeting Abstract

    Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Döhner, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Isogenic MDS-RS patient-derived iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant hematopoietic stem/progenitor cells
    Meeting Abstract

    Asimomitis, G.; Deslauriers, A. G.; Kotini, A. G.; Bernard, E.; Esposito, D.; Olszewska, M.; Spyrou, N.; Ossa, J. A.; Mortera-Blanco, T.; Koche, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interviews of patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) enrolled in 2 lisocabtagene maraleucel (liso-cel) trials on their treatment experience for 3 months after infusion
    Meeting Abstract

    Siddiqi, T.; Jaeger, U.; Moshkovich, O.; Braverman, J.; Liu, F. F.; Lanar, S.; Miera, M.; Shah, S.; Devlen, J.; Salles, G.
    Blood (2021)

    Fulltext@MSK | Save
  • Estimating selection bias in previous monoclonal gammopathy of undetermined significance research - the importance of screening: Results from the population-based screening study Iceland screens, treats or prevents multiple myeloma (iStopMM)
    Meeting Abstract

    Sigurbergsdóttir, A. Ý.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Expert curation of somatic FLT3 variants by the ClinGen somatic hematologic cancer taskforce (ClinGen HCT)
    Meeting Abstract

    Shao, X.; Rao, S.; Mani, C.; Saliba, J.; He, R.; Kesserwan, C.; Danos, A.; Sheta, L.; Terraf, P.; Raca, G.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in patients with relapsed/refractory B-cell malignancies
    Meeting Abstract

    Shah, B. D.; Jacobson, C.; Solomon, S. R.; Jain, N.; Johnson, M. C.; Vainorius, M.; Yu, L.; Heery, C. R.; List, A. F.; He, F.; more...
    Blood (2021)

    Fulltext@MSK | Save